Publications by authors named "J-S Diao"

Objective: To compare long-term quality of life (QOL) outcomes in breast cancer survivors who received breast-conserving surgery with radiotherapy (BCS+RT) with those who received a mastectomy and reconstructive surgery (Mast+Recon) without radiotherapy and identify other important factors.

Background: The long-term differences in patient-reported QOL outcomes following BCS+RT and Mast+Recon are not well understood.

Methods: We identified patients from the Texas Cancer Registry with stage 0-II breast cancer diagnosed in 2009-2014 after BCS+RT or Mast+Recon without radiotherapy.

View Article and Find Full Text PDF

The vital signs—temperature, heart rate, respiratory rate, and blood pressure—are indispensable in clinical decision-making. These metrics are widely used to identify physiologic decline and prompt investigation or intervention. Vital sign monitoring is particularly important in acute care settings, where patients are at higher risk and may require additional vigilance.

View Article and Find Full Text PDF

Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18-21 and are established driver mutations in non-small cell lung cancer (NSCLC). Targeted therapies are approved for patients with 'classical' mutations and a small number of other mutations. However, effective therapies have not been identified for additional EGFR mutations.

View Article and Find Full Text PDF

Background: Variable definitions and an incomplete understanding of the gradient of reverse cardiac remodeling following continuous flow left ventricular assist device (LVAD) implantation has limited the field of myocardial plasticity. We evaluated the continuum of LV remodeling by serial echocardiographic imaging to define 3 stages of reverse cardiac remodeling following LVAD.

Methods: The study enrolled consecutive LVAD patients across 4 study sites.

View Article and Find Full Text PDF

Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified alterations in a subset of lung adenocarcinomas and found expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in axis mutations, suggesting a co-oncogenic driver role in these molecular settings.

View Article and Find Full Text PDF